Ugandan,Ministry of healthy clarification on covid 19 virus

We need UPDF at Entebbe airport!!!! We are tired of these goons who do not love uganda

We need updf in Entebbe ASAP. Entebbe is becoming susceptible to foreigners from high risky countries affected by covid19. If this is not done quickly, Entebbe could turn into an epicenter of the Wuhan virus. Ruth Achieng is doing a great job but she's needs surport. The Chinese used their military to manage stiuations that wu'd compromise their efforts and now they are wining the war over covid19.

And these extortionist will be the ones to start blaming the gorvenment!!!!

What Telecom companies are saying about Corona virus

Rwandan and Corona virus today...Pray for our neighbors

7 promising Corona virus vaccine trials

Despite World Health Organisation warning last month that the first COVID-19 vaccine trials would come no sooner than after three to four months, quite a few pharmaceutical enterprises have ramped up efforts to attempt to roll out their much-coveted brainchildren ahead of schedule.
Here are the most discussed COVID-19 vaccine options that are approaching clinical tests and which will be conducted on people (if they are not already) sometime soon.
1. Russia's 'Vector'
The Russian consumer rights watchdog
Rospotrebnadzor announced on 20 March that its Novosibirsk-based research centre "Vector" had already started testing vaccines in the country, so the mass production of them could be launched in the fourth quarter of 2020. Although the substance hasn’t yet been named, the prototypes are mRNA, peptide, and subunit vaccines.
There are quite a few promising ventures by other countries, predominantly China, which have already entered stages 1-3 of clinical testing, or are just on the verge of doing so.
2. Chinese Gilead Sciences’ Remdisivir
The vaccine is tasked with easing patients’ fever and helping them to get out of hospital after no more than two weeks, Statnews wrote. The drug, which was also previously used in an Ebola virus study, is applied intravenously and is currently being tested by China (in phase 3) on 1,000 patients diagnosed with the coronavirus infection.
3. Ascletis Pharma's Venture
Somewhat less close to clinical testing is a development by another Chinese drug maker, Ascletis Pharma - a hybrid of two antiviral medicines: one approved for HIV and one approved for hepatitis C - anoprevir and ritonavir respectively. The company recently enrolled 11 patients with coronavirus-induced pneumonia and administered the combination, later boasting that the patients were successfully cured.
4. Moderna Therapeutics' MRNA-1273
Another Chinese enterprise, Moderna Therapeutics, has meanwhile entered phase 1 of clinical tests with its mRNA-1273, a vaccine candidate identified within just 42 days of tracking the novel coronavirus. The synthetic strand of the messenger known as mRNA is to convince human cells to release natural COVID-19 antibodies into the blood. The company is working with the National Institutes of Health and if mRNA-1273 proves to be safe, Moderna will enrol more patients to determine whether the vaccine safeguards from the infection. Among those who received the first jab were four American volunteers at the Kaiser Permanente research facility in Seattle, Washington.
5. Tianjin-headquartered CanSino Biologics Project
The marketer of the Ebola vaccine, this company is yet another entity scrambling to compete with all the rest in the development of an effective preventive measure against COVID-19. More specifically, it is trying to marry the coronavirus’ genetic code with a less dangerous virus and clinical tests, already approved by the Chinese authorities, are due to start in the near future.
6. CureVac: US-German Apple of Discord
There has reportedly been a tug of war lately between the US and Germany over a promising firm called CureVac, which is based in Tübingen, but also has branches in Frankfurt and the US state of Massachusetts. US President Donald Trump has reportedly been offering hefty sums to German scientists working on a vaccine in a bid to secure rights to their prospective brainchild, while other reports stated that Berlin has likewise tried to offer the promising company financial incentives for it to proceed with research in its home country. Last Friday, co-founder Florian von der Mülbe, who is in charge of the firm’s production, told Reuters that they had begun to pore over a slew of possible vaccines, with the two most viable ones expected to be picked later on for clinical testing, with human trials preliminarily expected in late summer.
7. San Diego-based Arcturus Therapeutics' RNA Editing
The company is working on a vaccine that heavily relies on engineering RNA, so that the edited version of the virus would encode proteins that would protect against infection and load it into a liquid nanoparticle. The approach is believed to promise a better immune response at a lower vaccine dose than mRNA approaches. The company is planning to kickstart human trials as quickly as possible.
As per Worldometrics.info, the overall number of coronavirus infections has topped 245,850 around the globe, with the death toll exceeding 10,000. Italy has become the new epicentre of the pandemic with 3,405 having died of coronavirus-related illnesses, overtaking China’s death toll by more than 150. To date, 88,441 people are registered to have recovered around the world.

Latest on Corona virus

Numerous countries have imposed travel bans and introduced 14-day quarantines for citizens coming home amid growing numbers of infected. Outside China, where the COVID-19 was originally registered back in December, the worst-hit countries are Italy, Iran, and Spain, with Germany and the US also reporting mass increases in numbers.
Worldwide, the virus has infected more than 255,300 people in 163 nations, with 10,444 deaths, Johns Hopkins University reported on its global virus tracking website.
According to the World Health Organisation (WHO), there are at least 209,000 coronavirus cases in over 120 countries, with the death toll surpassing 8,700. At the same time, around 90,000 of those infected have already recovered from the disease.

The Tsirkon hypersonic missile will be test-fired for the first time this year in spring from the Admiral Gorshkov frigate, a source in the Russian defence industry said.

For the first time, the Tsirkon was test-launched from the Admiral Gorshkov in January in the Barents Sea, home to Russia’s Northern Fleet.

“The second test – but the first one this year – is scheduled for this spring. The missile will be test-fired from Admiral Gorshkov frigate. The tests are underway”, the source said.

The Tsirkon, a scramjet-powered maneuverable anti-ship cruise missile capable of accelerating to speeds of up to 11,100 km an hour, is one of half-a-dozen or so strategic systems being developed by Russia’s military.

The Tsirkon is believed to have a flight range of over 1,000 km, and is expected base aboard both surface ships and marine ships, including vessels equipped to carry existing Kalibr-class cruise missiles. The missile is also widely expected to be fitted aboard the new Husky class fifth-generation nuclear submarine presently in development